Myo-inositol enhances teratogenicity of valproic acid in the mouse

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 76, Issue 3, 2006, Pages 200-204

  Massa, Valentina ^a,b   Wlodarczyk, Bogdan ^b   Giavini, Erminio ^a   Finnell, Richard H ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Exencephaly; myo inositol; NTDs; Valproic acid

Indexed keywords

INOSITOL; VALPROIC ACID;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; DEPLETION; DRUG EXPOSURE; EMBRYO; EMBRYO DEVELOPMENT; EMBRYO RESORPTION; FEMALE; FETUS; FETUS WASTAGE; FETUS WEIGHT; LM BC MOUSE; MATERNAL WEIGHT; MOUSE; MOUSE STRAIN; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; SKELETON MALFORMATION; SWV FNN MOUSE; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; DRUG SYNERGISM; EMBRYO LOSS; FEMALE; FETAL WEIGHT; INJECTIONS, INTRAPERITONEAL; INOSITOL; MICE; MICE, INBRED STRAINS; NEURAL TUBE DEFECTS; PREGNANCY; SPECIES SPECIFICITY; TERATOGENS; VALPROIC ACID;

ANIMALIA;

EID: 33645500097     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20228     Document Type: Article

References (36)

1. Bailey DN, Briggs JR. 2005. Valproic acid binding to human serum and human placenta in vitro. Ther Drug Monit 27:375-377.
2. Beemster P, Groenen P, Steegers-Theunissen R. 2002. Involvement of inositol in reproduction. Nutr Rev 60:80-87.
3. Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH. 2000. Valproic acid-induced alterations in growth and neurotrophic factor gene expression in murine embryos [corrected]. Reprod Toxicol 14:1-11.
4. Dietl J. 2005. Maternal obesity and complications during pregnancy. J Perinat Med 33:100-105.
5. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. 1984. The fetal valproate syndrome. Am J Med Genet 19:473-481.
6. Finnell RH, Bennett GD, Karras SB, Mohl VK. 1988. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38:313-320.
7. Finnell RH, Burn J. 2000. Effect of anti-epileptic drugs on intrauterine growth. Lancet 356:1537-1538.
8. Finnell RH, Waes JG, Eudy JD, Rosenquist TH. 2002. Molecular basis of environmentally induced birth defects. Annu Rev Pharmacol Toxicol 42:181-208.
9. Fisher SK, Novak JE, Agranoff BW. 2002. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 82:736-754.
10. Fowler DW, Eadie MJ, Dickinson RG. 1989. Transplacental transfer and biotransformation studies of valproic acid and its glucuronide(s) in the perfused human placenta. J Pharmacol Exp Ther 249:318-323.
11. Greene ND, Copp AJ. 1997. Inositol prevents folate-resistant neural tube defects in the mouse. Nat Med 3:60-66.
12. Greene ND, Copp AJ. 2005. Mouse models of neural tube defects: investigating preventive mechanisms. Am J Med Genet C Semin Med Genet 135:31-41.
13. Haneda M, Kikkawa R, Arimura T, Ebata K, Togawa M, Maeda S, Sawada T, Horide N, Shigeta Y. 1990. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism 39:40-45.
14. Hovland DN Jr, Machado AF, Scott WJ Jr, Collins MD. 1999. Differential sensitivity of the SWV and C57BL/6 mouse strains to the teratogenic action of single administrations of cadmium given throughout the period of anterior neuropore closure. Teratology 60:13-21.
15. Ju S, Greenberg ML. 2003. Valproate disrupts regulation of inositol responsive genes and alters regulation of phospholipid biosynthesis. Mol Microbiol 49:1595-1603.
16. Khandelwal M, Reece EA, Wu YK, Borenstein M. 1998. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology 57:79-84.
17. Lammer EJ, Sever LE, Oakley GP Jr. 1987. Teratogen update: valproic acid. Teratology 35:465-473.
18. Li J, Foote RH. 1995. Effect of inositol and glycine with increasing sodium chloride and constant osmolality on development of rabbit embryos. J Assist Reprod Genet 12:141-146.
19. Lundberg YW, Cabrera RM, Greer KA, Zhao J, Garg R, Finnell RH. 2004. Mapping a chromosomal locus for valproic acid-induced exencephaly in mice. Mamm Genome 15:361-369.
20. Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. 1996. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen 16:97-108.
21. Menegola E, Broccia ML, Prati M, Giavini E. 1998. Stage-dependent skeletal malformations induced by valproic acid in rat. Int J Dev Biol 42:99-102.
22. Menegola E, Broccia ML, Di Renzo F, Giavini E. 2002. Comparative study of sodium valproate-induced skeletal malformations using single or double staining methods. Reprod Toxicol 16:815-823.
23. Mistry KP, Beyer-Mears A, Diecke FP. 1993. Mechanisms for D-glucose inhibition of myo-inositol influx into rat lens. Diabetes 42:1737-1744.
24. Nau H, Zierer R, Spielmann H, Neubert D, Gansau C. 1981. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 29: 2803-2814.
25. Nau H. 1985. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243-250.
26. Nau H. 1994. Valproic acid-induced neural tube defects. Ciba Found Symp 181:144-152; discussion 152-160.
27. Paulson RB, Sucheston ME, Hayes TG, Paulson GW. 1985. Teratogenic effects of valproate in the CD-1 mouse fetus. Arch Neurol 42:980-983.
28. Perucca E. 2002. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695-714.
29. Reece EA, Wu YK. 1997. Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant. Am J Obstet Gynecol 176:790-797; discussion 797-798.
30. Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, Harwood AJ, Belmaker RH, Greenberg ML, Agam G. 2004. Valproate decreases inositol biosynthesis. Biol Psychiatry 56:868-874.
31. Shaw GM, Carmichael SL, Yang W, Schaffer DM. 2005. Periconceptional dietary intake of myo-inositol and neural tube defects in offspring. Birth Defects Res A Clin Mol Teratol 73:184-187.
32. Sonoda T, Ohdo S, Ohba K, Okishima T, Hayakawa K. 1990. Teratogenic effects of sodium valproate in the Jc1: ICR mouse fetus. Acta Paediatr Jpn 32:502-507.
33. Tomson T, Perucca E, Battino D. 2004. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 45:1171-1175.
34. Utoguchi N, Audus KL. 2000. Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int J Pharmacol 195:115-124.
35. Vaden DL, Ding D, Peterson B, Greenberg ML. 2001. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 276:15466-15471.
36. Wide K, Winbladh B, Kallen B. 2004. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 93:174-176.